Brain ethanolamine phospholipids, neuropathology and cognition: A comparative post-mortem analysis of structurally specific plasmalogen and phosphatidyl species

Dayan B. Goodenowe* and Vijitha Senanayake
Prodrome Sciences USA LLC, Temecula, CA, United States

Reduced cognition in the elderly is associated with low levels of plasmalogens and high levels of lipid rafts, amyloid plaques, and neurofibrillary tangles in the temporal cortex. A systematic integrative analysis of key indices of these pathologies to determine their collective and independent contributions to cognition was performed. Levels of four phosphatidylethanolamines (PE) and four ethanolamine plasmalogens (PL) of identical sn-1 carbon length and desaturation (stearic, 18:0) and identical sn-2 fatty acid compositions of varying side chain lengths and degrees of unsaturation (oleic, 18:1; linoleic, 18:2; arachidonic, 20:4; docosahexaenoic, 22:6), flotillin-1 expression and amyloid plaque and neurofibrillary tangle densities were measured in inferior temporal cortex tissue from 100 elderly subjects (Rush University Memory and Aging Project, 88.5 ± 5.8 years old). Subjects were evenly distributed with respect to gender (52/48, F/M) and cognitive status (38/24/38, no cognitive impairment/mild cognitive impairment/Alzheimer's dementia) proximate to death. Multivariate logistic regression analyses were used to determine the relative and collective associations of the neuropathological indices with cognition. Higher levels of tangles, amyloid, or flotillin and lower levels of PL 18:0/22:6 were significantly associated with lower cognition in the base model (adjusted for age, sex, education). Multivariate analysis revealed that only PL 18:0/22:6 (β = 0.506; p < 0.00001), tangles (β = 0.307; p < 0.01), and flotillin (β = 0.2027; p < 0.05) were independently associated with reduced cognition. PL 18:0/22:6 and PE 18:0/22:6 levels were independently associated with cognition in the presence of tangles, amyloid, and flotillin, but only PL 18:0/22:6 retained its association with cognition when both PL and PE 18:0/22:6 were included in the model indicating that PE 18:0/22:6 levels were associated with PL 18:0/22:6, not cognition. Only high brain levels of PL 18:0/22:6 (>mean+1SD) was predictive of normal cognition (coef = 1.67, p < 0.05) and non-demented state (coef = −2.73, p < 0.001), whereas low levels of PL 18:0/22:6 and high levels of tangles or flotillin were predictive of dementia. The association of high brain polyunsaturated (PUFA)-PL levels with better cognition was independent of amyloid plaque, neurofibrillary tangle, PE, and flotillin-1 expression. Maintenance or augmentation of brain docosahexaenoic (DHA)-PL levels...
warrants further investigation as a target for preventing cognitive decline or improving cognition in the elderly, respectively.

**KEYWORDS**
plasmalogen, amyloid, neurofibrillary tangle, flotillin, docosahexaenic acid, cognition, Alzheimer’s, brain

**Introduction**

Neurodegeneration leading to dementia and death is emerging as the most important age-related disease of our time. The average time to death from a diagnosis of dementia is only 4.5 years (Xie et al., 2008) and Alzheimer’s disease (AD) is the predominant form of dementia in the elderly. The economic and health cost of dementia is enormous and growing due to an increasingly aged population (Alzheimer’s Association, 2018). Dementia in the elderly is a neuropathological disease. Amyloid plaques and neurofibrillary tangles are pathological hallmarks of AD and were once thought to be not just biomarkers of neuropathological decline, but causative of neuropathological and functional decline in the elderly (Hardy and Selkoe, 2002). However, recent clinical trials have cast doubt on the putative causative roles of these well-established neuropathological markers on cognitive decline (Kozin et al., 2018). The presence of high amyloid plaque densities in cognitively normal persons illustrates that there must be other neuropathological features that modulate the associations of these historical pathologies with cognition (Negash et al., 2011) and which are more proximate to the biochemical mechanisms that are required for normal cognitive function.

Changes in neuronal membrane composition are directly implicated as potential causative mechanisms involved in the pathological accumulation of amyloid (Nitsch et al., 1992) and reduced neuronal synaptic activity (Wurtman, 1992). A higher density of cholesterol-rich lipid raft regions are associated with increased β-secretase activity and increased Aβ1-42 production (Kojro et al., 2001; Cordy et al., 2003) and a higher density of polyunsaturated plasmalogen rich regions is associated with increased α-secretase activity and decreased Aβ1-42 production (Wood et al., 2011a). Membrane fusion dynamics, the biophysical process through which neurotransmitters are released into the synapse, is dependent upon membrane levels of polyunsaturated fatty acid (PUFA) containing ethanolamine plasmalogens (PL) (Glaser and Gross, 1995). PL is emerging as both a diagnostic and therapeutic target for neuropathological decline and dementia (Goodenowe et al., 2007). Brain PL levels are lower in AD than age-matched controls (Ginsberg et al., 1995; Han et al., 2001; Wood et al., 2011a; Igarashi et al., 2011; Otoki et al., 2021) and low brain levels correlate with low serum levels (Wood et al., 2011a). Serum PL levels correlate with cognition in subjects diagnosed with probable AD, in AD subjects at diagnosis who were later confirmed by autopsy, and in serum samples collected at time of death in subjects with post-mortem AD pathology (Goodenowe et al., 2007). Reductions in metabolic pathways involved in PL biosynthesis are associated with lower cognition (Astarita et al., 2010). Relation of PL and other phospholipid species in the brain in individuals with different cognitive categories (Clinical Dementia Rating) has been previously studied (Han et al., 2001).

Studying the effects of plasmalogen supplementation is challenging due to the complex distribution of molecular species in mammalian tissues (Han et al., 2001) which renders measuring the effects of a single type of plasmalogen difficult using animal extracts. Their extensive gut metabolism and acid degradation during oral administration (Fallatah et al., 2020) creates additional scientific challenges. To overcome these issues, 1-O-alkyl-2-acylglycerols were developed as metabolic precursors to plasmalogens. These precursors can be synthesized to contain specific sn-1 alcohols and specific sn-2 fatty acid side chains. They are stable, orally bioavailable, and dose-dependently elevate PL levels in vitro and in vivo corresponding to the sn-1 fatty alcohol and sn-2 fatty acid of the precursor (Mankidy et al., 2010; Wood et al., 2011a; Wood et al., 2011b). These precursors enable researchers to precisely assess the effects of plasmalogen supplementation. These plasmalogen precursors are neuroprotective in animal models of Parkinson’s (Miville-Godbout et al., 2016) and multiple sclerosis (Wood et al., 2011a) and improve neurological function in neurologically compromised animals (Gregoire et al., 2015).

The extent to which PL interact with and modulate the association of pathology with cognition in the human brain are not known. We therefore sought to investigate in greater detail the associations between cognition, canonical neuropathology and a series of structurally specific membrane phospholipids known to be altered in persons with AD pathology or reduced cognition. All neurological functions are dependent upon the presynaptic release of neurotransmitters and the subsequent postsynaptic interaction of these neurotransmitters on postsynaptic receptors/receptors. Cognition is dependent upon cholinergic neuron integrity and function (Blusztaijn and Wurtman, 1983; Wurtman et al., 1985; Wurtman, 1992). Presynaptic cholinergic axon terminals are unique among neurons in that both the release of its neurotransmitter, acetylcholine, and the reabsorption of the neurotransmitter precursor, choline, is dependent upon membrane fusion due to the unique cellular location of the re-uptake protein. The choline high affinity transporter (CHT) is not constitutively expressed on the presynaptic membrane like the
Materials and methods

Brain samples

One hundred inferior temporal cortex brain samples were obtained from the Rush University Memory and Aging Project (MAP). Rush MAP is a community-based study that enrolls older persons without known dementia who agreed to annual clinical and cognitive evaluations and to donate their brains after death (Bennett et al., 2012; Yu et al., 2017). Brain samples were fractioned and immediately frozen and stored at −80°C until analysis (average post-mortem interval of approximately 8 h). All participant samples were processed under the same protocol and no significant differences in sample collection times were observed (Table 1). At the last clinical visit prior to the death and subsequent autopsies of the donors, 38 had no cognitive impairment (NCI), 44 had mild cognitive impairment (MCI) and 38 had dementia of the Alzheimer’s type (AD). Genders of the study participants were equally distributed (52 females and 48 males) and the average age was 88.5 ± 5.8 years old. A uniform structured clinical evaluation was performed to document the level of cognition and the presence of AD, MCI, and other causes of cognitive impairment. Neuropsychological indices of cognition were summarized as a global measure of cognition (Gcog) based on the average z-score of 19 tests in each study, using the means and standard deviations from the baseline visit. Participant characteristics and the number of people in each clinical category is given in Table 1.

Neuropathological measurements

Global cortical amyloid load and PHF-tangle density were assessed separately using immunohistochemical methods (Yu et al., 2017). Braak staging and CERAD scoring were based on blinded assessment by a trained neuropathologist (Yu et al., 2013). Braak Stage is a semiquantitative measure of severity of neurofibrillary tangle (NFT) pathology (range 1–6; 6 = severe neocortical involvement). CERAD score is a semiquantitative measure of neuritic plaques (range: 1–4; 1 = definite AD; 4 = No AD). Flotillin-1 (FLOT1) mRNA expression was measured by qPCR. Total messenger RNA was extracted from cells using TRIzol™ following the manufacturer’s instructions (ThermoFisher). qPCR was conducted using a Nanodrop 1000 (ThermoFisher). The primers used were as follows: forward: 5′-CCCATCTCAGTCACGTGGCATTT-3′ and reverse: 5′-CCGCGCA ACATCTCCTGTTC-3′ for FLOT1 and β-actin was used as an internal reference.
### Table 1: Demographic, clinical and biochemical summary of the study cohort.

| Variable | NCP | MCI | AD | Cognitively normal | Non-cognitively normal | Non-demented | Demented | p-value |
|----------|-----|-----|----|---------------------|------------------------|--------------|----------|---------|
|          | Mean (SD) | Mean (SD) | Mean (SD) | p-value | Mean (SD) | Mean (SD) | p-value | Mean (SD) | Mean (SD) |
| Gender   | Male (n) | 18 | 11 | 19 | 9.5e−1 | 18 | 30 | 9.2e−1 | 29 | 19 | 7.5e−1 |
|          | Female (n) | 20 | 13 | 19 | 20 | 32 | 33 | 19 |
| Age (SD) | 86.7 (6.16) | 86.6 (5.66) | 90.2 (5.01) | 2.6e−2* | 86.7 (6.16) | 89.6 (5.29) | 1.4e−2* | 87.4 (5.99) | 90.2 (5.01) | 1.7e−2* |
| Education (SD) | 14.2 (2.79) | 14.7 (2.16) | 14.8 (3.20) | 1.35e−1 | 14.2 (2.79) | 14.7 (2.82) | 3.4e−2* | 14.4 (2.55) | 14.8 (3.19) | 4.7e−1 |
| Post-mortem Interval (min) | 369.4 (136.3) | 492.5 (320.2) | 394.2 (272.0) | 5.3e−1 | 369.4 (136.3) | 431.3 (292.4) | 2.3e−1 | 416.6 (230.7) | 394.2 (272.0) | 6.6e−1 |
| MMSE | 28.4 (1.59) | 25.6 (2.99) | 12.0 (8.05) | < 1.0e−5* | 28.4 (1.59) | 17.4 (9.32) | < 1.0e−5* | 27.3 (2.61) | 12.0 (8.04) | < 1.0e−5* |
| Grocott | 0.213 (0.421) | −0.436 (0.33) | −1.91 (1.01) | < 1.0e−5* | 0.213 (0.42) | −1.33 (1.08) | < 1.0e−5 | −0.04 (0.50) | −1.91 (1.21) | < 1.0e−5* |

### Brain

| Region | n | n | n | p-value | n | n | p-value | n | n | p-value |
|--------|---|---|---|---------|---|---|---------|---|---|---------|
| I/II   | 13 | 6 | 2 | < 1.0e−3* | 13 | 8 | < 1.0e−3* | 19 | 2 | < 1.0e−3* |
| III    | 14 | 7 | 5 | 1.32e−1 | 14 | 12 | 21 | 5 |
| IV     | 11 | 5 | 12 | 1.91 (10.8) | 11 | 17 | 16 | 12 |
| V/VI   | 0 | 6 | 19 | 1.0e−4* | 0 | 25 | 6 | 19 |

### Cerebrospinal fluid

| Parameter | n | n | p-value | n | n | p-value | n | n | p-value |
|-----------|---|---|---------|---|---|---------|---|---|---------|
| 1         | 6 | 4 | 25 | < 1.0e−3* | 6 | 29 | 8.0e−3* | 10 | 25 | < 1.0e−3* |
| 2         | 12 | 7 | 9 | 1.0e−4* | 12 | 16 | 19 | 9 |
| 3         | 5 | 5 | 2 | 1.0e−4* | 5 | 7 | 10 | 2 |
| 4         | 15 | 8 | 2 | 1.0e−4* | 15 | 10 | 23 | 2 |

### Tissue ethanolamine phospholipid measurements

Brain samples were processed essentially as described in a previous publication (Miville-Godbout et al., 2016). Briefly, brain samples were randomized prior to processing and then homogenized and ground to a fine powder in liquid nitrogen. Tissue samples were aliquoted (1 mg), water (200 μl) was added and samples were sonicated in an ice bath. After adding 600 μl of EtOAc, samples were shaken at 2000 rpm for 15 min followed by a 10 min centrifugation at 2851 g. An aliquot of the upper organic layer (36 μl) was then diluted with 420 μl of a solution of 0.5%...
Statistical analyses

In descriptive analyses, demographic and clinico-pathological parameters among diagnostic categories (NCI, MCI and AD) were compared using chi-square or Fishers’s exact tests for categorical variables and analysis of variance for continuous variables. PL and PE analytes were first mean normalized and then log transformed to reduce skewness.

For continuous outcomes such as Gcog, we first screened potential predictors by examining correlations with the outcome and then fit multiple linear regression models including variables of interest and terms to adjust for age, sex and education. For continuous predictors, associations are shown per SD of the predictor. Stata 15.0 was used to perform statistical analyses; statistical significance is \( p < 0.05 \) in all analyses.
Association of degree of unsaturation and chain length of PL and PE with cognition

We examined the association between brain levels of monounsaturated fatty acid (MUFA) and PUFA-containing (at sn-2) PE and PL with Gcog and found that higher levels of each PE species predicted higher Gcog irrespective of the level of unsaturation at the sn-2 position. However, only higher levels of highly unsaturated AA (20:4, n-6) or DHA (22:6, n-3)-containing PL was associated with higher Gcog.

Since it appeared that the coefficient of association of PL and PE species with Gcog was affected by the degree of unsaturation and chain length of the sn-2 sidechains, we further examined the association of the change in sn-2 chain length (18 carbon to 22 carbon) and the degree of unsaturation (one double bond to six double bonds) with cognition in each phospholipid type. We observed that for PE, the predicted Gcog values after adjusting for age, sex and education changed little based on the sn-2 side chains (Figure 1A). However, for PL, the regression slopes increased incrementally with increasing sn-2 chain length and unsaturation (Figure 1B). As expected, pathological markers were negatively associated with cognition (Table 3).

Similarly, the strength of the association (β-coefficient) increased with increasing sn-2 unsaturation and chain length in both phospholipid types and DHA-containing PL and PE had the strongest association with Gcog (Table 3). Since our objective was to examine how phospholipids modulate the association of brain pathology with cognition, we limited further statistical analyses to these two phospholipids.

**TABLE 3** Association of clinical and biological variables with cognition.

| Variable* | Gcog |
|-----------|------|
| n         | Coefb | p    | Adj $R^2$ |
| PE18:0/18:1 | 99  | 0.4950 | 6.0e−06* | 0.2346 |
| PE18:0/18:2 | 99  | 0.4882 | 1.7e−05* | 0.2180 |
| PE18:0/20:4 | 99  | 0.5983 | 4.1e−08* | 0.3095 |
| PE18:0/22:6 | 99  | 0.5989 | 2.4e−08* | 0.3174 |
| PL 18:0/18:1 | 99  | 0.0380 | 7.4e−01 | 0.0483 |
| PL 18:0/18:2 | 99  | 0.1692 | 1.4e−01 | 0.0691 |
| PL 18:0/20:4 | 99  | 0.4981 | 9.0e−06* | 0.2283 |
| PL 18:0/22:6 | 99  | 0.6191 | 9.6e−09* | 0.3300 |
| Amyloid | 98  | −0.3901 | 5.7e−04* | 0.1499 |
| Tangles | 99  | −0.5510 | 6.7e−07* | 0.2685 |
| Flotillin | 94  | −0.2601 | 3.4e−02* | 0.0879 |

*Multiple regression analysis with phospholipids or pathological parameters as the independent variable and Gcog as the dependent variable. Gcog represents a composite measure of cognitive function assessed by a battery of cognitive tests.

bCoefficients for continuous variables expressed per Standard Deviation; Models were adjusted for age, education, and gender. *p < 0.05.

Multivariate associations of brain pathology, membrane markers and phospholipids with cognition

We then examined the association of amyloid and tangles with Gcog. As expected, both amyloid and tangle density, which are hallmarks of AD-related brain pathology, predicted lower Gcog.
TABLE 4 Association of amyloid, tangles, flotillin and phospholipids with cognition.

| Variable          | Gcog*  |
|-------------------|--------|
|                   | Base model | Model A | Model B | Final model |
| PL 18:0/22:6 (Coef) | Not Included | Not Included | 0.5194* | 0.5058*** |
| PE 18:0/22:6 (Coef) | Not Included | Not Included | −0.0520 | Not Included |
| Amyloid (Coef)     | −0.2435* | −0.2315* | −0.1267 | Not Included |
| Tangles (Coef)     | −0.4792*** | −0.4569*** | −0.2815* | −0.3069 ** |
| Flotillin (Coef)   | Not Included | −0.1605 | −0.2029 | −0.2027* |
| Age (Coef)         | −0.2168* | −0.1574 | −0.2145 | −0.2109* |
| Education (Coef)   | 0.1803 | 0.1501 | 0.0622 | 0.0628 |
| Male sex (Coef)    | −0.0811 | −0.0700 | −0.0005 | −0.0053 |
| F                 | 9.18*** | 7.71*** | 9.39*** | 12.84*** |
| Adjusted R²       | 0.2965 | 0.3045 | 0.4219 | 0.4331 |
| N                 | 98.00 | 93.00 | 93.00 | 94.00 |

Independent multivariate regression models with Gcog as the outcome and phospholipids and pathological parameters as variables.

*Gcog (Global Cognition) represents a composite measure of cognitive function assessed by a battery of cognitive tests.

**Coef (Coefficient of association) for continuous variables expressed per Standard Deviation; Base Model: demographics + amyloid and tangles; Model A: Base Model + Flotillin; Base Model + Flotillin and DHA ethanolamine phospholipids; Final Model: only demographics and variables independently associated with Gcog after multivariate assessment (p < 0.05). *p < 0.05; **p < 0.01, ***p < 0.0001.

(Base Model, Table 4). We then examined whether the expression of flotillin-1, which is a marker of lipid rafts, modulate the association of amyloid and tangles with Gcog in the Base Model. Flotillin-1 was not significantly associated with cognition when amyloid and tangles were in the model and the associations of amyloid and tangles with Gcog remained intact after the addition of flotillin-1 to the model (Model A, Table 4), indicating the independence of the association of amyloid and tangles with Gcog. When we then added both PE 18:0/22:6 and PL 18:0/22:6, the phospholipids most associated with Gcog from Table 3, to the model and found that these phospholipids reduced the strength of the association of amyloid and tangles with Gcog and increased the association of flotillin-1 with Gcog (p = 0.053) (Model B, Table 4). The strengths of the associations (determined by the β-coefficient) of these pathological markers with cognition weakened in relation to the base model (adjusted only for age, sex and education; Table 3) when PE and PL 18:0/22:6 were added to the model, indicating that the brain levels of these phospholipids contribute to the variability explained by these pathological markers (Model B, Table 4).

However, the association of PE 18:0/22:6 with Gcog observed in Table 3 disappeared under multivariate analysis that included PL 18:0/22:6 (Model B, Table 4). Therefore, to derive the final model, we removed PE 18:0/22:6 and other variables that were not associated with Gcog under multivariate conditions. Removal of these variables resulted in an increase in the variance in cognition explained by the model (Final Model, Table 4). The Final Model resulted in an improvement of the association of flotillin-1 with Gcog (p < 0.05). Brain amyloid levels were not associated with Gcog under multivariate analysis (Model B, Final Model, Table 4). When compared to the model without PL 18:0/22:6, inclusion of PL 18:0/22:6 in the model strengthened the association of flotillin-1 with Gcog.

Modulation of the association between cognition and PE 18:0/22:6 by PL 18:0/22:6

When the association between cognition and PE 18:0/22:6 in Table 3 is compared to Model B, Table 4 the addition of PL 18:0/22:6 was observed to affect this association. To investigate the relative and interactive associations of these two similar phospholipids on cognition, four predictive models were created (Figure 2). Figure 2A illustrates the association between PE 18:0/22:6 and cognition with and without PL 18:0/22:6 as a covariate. Inclusion of PE 18:0/22:6 completely neutralized the association between PE 18:0/22:6 and cognition. Figure 2B illustrates the association between PL 18:0/22:6 and cognition with and without PE 18:0/22:6 as a covariate. Inclusion of PE 18:0/22:6 had no effect on the association between PL 18:0/22:6 and cognition. These results indicate that cognition is directly associated with the level of PL 18:0/22:6 not PE 18:0/22:6.

Modulation of the association between cognition and amyloid, tangles and flotillin by PL 18:0/22:6

When the associations between cognition and amyloid, tangles and flotillin-1 in Table 3 and Table 4 (Model A) are compared, the association between cognition and tangles is minimally affected by amyloid and flotillin (−0.55 to −0.46), but the association between amyloid and cognition is reduced
almost in half (−0.39 to −0.23). When brain phospholipids are subsequently included (Model B), the association between tangles and cognition drops from −0.46 to −0.28 and the association between amyloid and cognition becomes insignificant (−0.23 to −0.13). To illustrate the effect of PL 18:0/22:6 on these associations, six predictive models were created to compare the associations between each of these pathologies and cognition with and without PL 18:0/22:6 in the model (Figure 3). Figure 3A illustrates the flattening of the association between tangles and cognition by PL 18:0/22:6. Figure 3B illustrates the flattening of the association between amyloid and cognition by PL 18:0/22:6. Amyloid is not associated with cognition when PL 18:0/22:6 is a covariate. Figure 3C illustrates that PL 18:0/22:6 has no modulatory effect on the association between flotillin-1 and cognition. What is illustrated in Figures 2, 3 which is not discernible from the data in Tables 3, 4 is the variance in cognition observed across the range of measured values of tangles, amyloid, flotillin-1 and PL 18:0/22:6. Gcog values ranged from just over 0 in persons with the lowest level of tangles to just under 1 in persons with the highest level of tangle density for a total variance in cognition of just under 2 Gcog units across the range of measured brain tangle density. The total variance in Gcog across the measured range of amyloid levels was approximately 0.5 Gcog units and the total variance of cognition across the range of flotillin-1 values was approximately 1.5 Gcog units. Whereas in Figure 2, the total variance in cognition across the range of PL 18:0/22:6 values was approximately 5 Gcog units (from −4 in persons with the lowest brain PL 18:0/22:6 levels to +1 in persons with the highest brain PL 18:0/22:6 levels).

Assessment of brain pathology, flotillin and PL 18:0/22:6 with normal cognition and dementia

Multivariate regression analyses identified brain levels of PL 18:0/22:6, tangles and flotillin-1 as key predictors of cognition. To understand the nature of these associations across the full range of their measured values, we categorized the levels of these variables into low (<mean−1SD), median (mean ± 1SD) and high (>mean+1SD) and used logistic regression to determine the associations of these categories with different ends of the measurable cognition range. The terms “no cognitive impairment, NCI” and “cognitively normal, CN” are not synonymous with high cognitive function. In fact, the range of cognitive performance in individual neuropsychometric tests in persons determined, clinically, to be NCI or CN represents a distribution with an equal number of persons above normal and an equal number of persons below normal, but above cognitive impairment (Bennett et al., 2006). Likewise, there is a distribution of cognition in persons determined, clinically, to be demented ranging from mild to severe dementia, but lower than a determination of questionable or mild cognitive impairment (MCI). Therefore, the prediction of CN from non-CN (MCI + dementia) and demented from non-demented (CN + MCI) is not an equal but opposite analysis. The lack of a negative association is not the same as the presence of a positive association. We reasoned that with these analyses, we would
be able to determine and compare the strength of the positive and negative associations of lower and higher levels of these variables with cognition.

The analysis results indicated that high brain PL 18:0/22:6 (>mean+1SD) predicted normal cognition and non-demented state, but low tangle, flotillin-1 or amyloid levels did not (Table 5). However, low brain PL 18:0/22:6 (<mean-1SD) and high levels of tangles and flotillin-1 (>mean+1SD) and intermediate levels of amyloid (mean ± 1SD) predicted dementia (Table 5).

Discussion

In our previous studies, we demonstrated that serum plasmalogen levels were associated with cognitive outcomes (Goodenowe et al., 2007; Wood et al., 2010; Goodenowe and Senanayake, 2019). We have also demonstrated neuroprotective effects of exogenous supplementation of plasmalogen precursors in animal models (Wood et al., 2011a; Gregoire et al., 2015; Miville-Godbout et al., 2016) and in a preliminary 4-month, escalating dose, open label study of a targeted equimolar formulation of PL 16:0/22:6 and PL 18:0/22:6 plasmalogen precursors in 22 cognitively impaired persons, blood levels of PL 16:0/22:6 and PL 18:0/22:6 were elevated by approximately 70% from baseline and this increase was associated with decreased malondialdehyde levels and increased catalase enzymatic capacity. Improved cognition and mobility were also reported (Goodenowe et al., 2022). Low brain and circulating serum plasmalogen levels in neurodegenerative diseases such as Alzheimer’s disease have been observed by multiple independent researchers and these
deficiencies are thought to contribute to defects in cellular membrane function (Ginsberg et al., 1995; Farooqui et al., 1997; Han et al., 2001; Dorninger et al., 2015). In this study, we sought to examine a specific class of brain membrane lipids (ethanolamine phospholipids) based upon their known high abundance in neuronal membranes (Han, 2005), diverse sn-1 and sn-2 speciation (Han et al., 2001), and their direct physiological role in membrane fusion/neurotransmitter release (Glaser and Gross, 1995). Similarly, we selected the temporal cortex, a brain region known to exhibit pathological (Braak and Braak, 1997; Scheff et al., 2011), morphological (Braak and Braak, 1991) and functional (Halawa et al., 2019) changes at the earliest clinically detectable stages of cognitive impairment and dementia as a relevant brain region of interest.

The major findings of this study are: 1) The association between brain levels of PL and cognition was observed to be dependent on the chain-length and the degree of unsaturation of the sn-2 fatty acid side chain. 2) The associations between PE species and cognition were observed to be indirect and mediated via their association with PL 18:0/22:6. 3) High levels (>mean±1SD) of PL 18:0/22:6 predicted normal cognition and low levels (<mean−1SD) predicted reduced cognition and dementia. In contrast, a high density of neurofibrillary tangles or high flotillin-1 expression was observed to be predictive of reduced cognition, but low levels were not predictive of normal cognition. 4) PL 18:0/22:6 modulated the associations between cognition and PE 18:0/22:6, tangles and amyloid.

A higher age is a primary epidemiological variable associated with lower cognition and our data confirm this association (Table 1). As expected, cognitive status (Gcog), neurofibrillary tangle density, amyloid plaque density, Braak Stage (V/VI), and CERAD score significantly differed between the diagnostic subgroups (Table 1). Each of the PE species and the two PUFA-containing PL species (18:0/20:4 and 18:0/22:6) significantly differed between the diagnostic categories indicating that a global loss in brain ethanolamine phospholipid species is associated with reduced cognition. Flotillin-1 expression was significantly higher in demented

| Variable | Cognitively | Non-demented vs. demented |
|----------|-------------|---------------------------|
|          | Abnormal vs. NCI | Coefficient (95% CI) | Coefficient (95% CI) |
| PL 18:0/22:6 | | | |
| <Mean−1SD | Ref | 2.73 (1.00 to 4.46)** |
| Mean ± 1SD | 0.56 (−0.82 to 1.95) | 1.52 (0.06 to 2.99) |
| >Mean+1SD | 1.67 (0.27 to 3.06)* | Ref |
| Tangles | | | |
| <Mean−1SD | 17.1 (−4108.5 to 4142.6) | Ref |
| Mean ± 1SD | 16.8 (−4108.8 to 4142.4) | 0.62 (−1.38 to 2.61) |
| >Mean+1SD | Ref | 4.85 (1.44 to 8.26)** |
| Flotillin | | | |
| <Mean−1SD | 0.74 (−0.93 to 2.41) | Ref |
| Mean ± 1SD | −0.13 (−1.38 to 1.12) | 1.65 (−0.35 to 3.65) |
| >Mean+1SD | Ref | 2.27 (0.012 to 4.52)* |
| Amyloid | | | |
| <Mean−1SD | 0.62 (−1.41 to 2.66) | Ref |
| Mean ± 1SD | 0.43 (−1.51 to 2.37) | 2.87 (0.57 to 5.17)* |
| >Mean+1SD | Ref | 1.53 (−1.15 to 4.20) |

*aLogistic regression analysis to determine the effects of low, medium and high levels of phospholipids and pathological parameters on cognitively normal state (NCI) and dementia diagnosis. Dummy variables were created from continuous variables of these parameters to derive categories representing low, medium and high levels. Each model was adjusted for age, sex and education in addition to PL 18:0/22:6, tangles, flotillin as continuous variables, when the corresponding categorical variable is not included in the model. NCI, No cognitive impairment.**p < 0.05; ***p < 0.01.
individuals, which is consistent with previously published results (Girardot et al., 2003). We observed that more double bonds (6>4>2>1) and higher carbon chain length (22>20>18) in the sn-2 fatty acid strengthened the association of PL species with cognition but had a minimal effect on the association between PE species levels and cognition. Neurotransmission involves both biophysical and biochemical processes. Prior to a putative neurotransmission event, neurotransmitter molecules are stored in presynaptic membrane-bound vesicles which isolate them from the intracellular metabolism of the presynaptic neuron. Upon receipt of a depolarizing action potential, the vesicles migrate to the outer presynaptic membrane where they fuse with and release the neurotransmitters into the extracellular synaptic cleft where they subsequently interact with protein receptors on the postsynaptic membrane of the adjacent neuron. Sufficient membrane levels of PUFA PL are required for this membrane fusion process to occur (Lohner, 1996). Efficient fusion of cellular membranes is required for effective neurotransmission (Yang et al., 2017). Membrane fusion efficiency was observed to be dependent on the amount of PL in the membrane as well as the structural composition of the PL. A longer chain length and higher degree of unsaturation of the sn-2 PL sidechain incrementally increased membrane fusion events. A direct comparison of PL and PE species of identical side chain compositions further illustrated the dependence of membrane fusion on membrane PL levels (Glaser and Gross, 1995). This is a plausible biophysical mechanism for the differential trends in the associations between PL and PE sn-2 sidechains with cognition observed in this study. Although brain plasmalogens have been shown to be lower in brain regions with AD-related pathology and the association of low serum PL levels with brain pathology have been demonstrated by us and others (Ginsberg et al., 1995; Farooqui et al., 1997; Han et al., 2001; Dorninger et al., 2015), to our knowledge this is the first direct demonstration of the compositional specificity of the PL association with cognition. Brain levels of PL with sn-2 fatty acids with longer chain length and a higher degree of unsaturation were associated with cognition whereas PL with sn-2 fatty acids with shorter chain length and a lower degree of unsaturation were not.

We examined whether the levels of PL 18:0/22:6 in the brain altered the associations between amyloid and tangles, the hallmarks of AD pathology, with cognition. Our data indicate that higher brain PL 18:0/22:6 levels decrease the strength of the association (β-coefficient) between amyloid and tangles with cognition, indicating that the association between brain pathology and cognition is affected by the level of PL 18:0/22:6 levels in the brain. These observations are consistent with the findings that amyloid and tangles do not correlate directly with cognition nor do they explain the variance of cognition in AD (Negash et al., 2011). Inclusion of PL 18:0/22:6 in the model, along with amyloid and tangles, increased the explained variance when cognition was the outcome of interest. Furthermore, when the variance in cognitive status across the full measured ranges of amyloid plaque density, neurofibrillary tangle density, flotillin-1 expression and PL 18:0/22:6 in temporal cortex were compared (Figures 1, 2) the cognitive status associated with highest versus lowest levels of these biomarkers was observed to be dramatically different. The variance in cognition across the range of amyloid density was about 0.5 Gcog units, and about 1.5 for tangles and flotillin-1, but was about 5 units for PL 18:0/22:6.

The association of PL 18:0/20:6 with cognition remained unchanged when adjusted for brain pathology (amyloid and tangles) and the increased explained variance in this model indicates that the amount of PL 18:0/20:6 in the brain is an independent contributor to cognition. Similarly, when adjusted for PL 18:0/22:6 levels, the association of PE 18:0/22:6 with cognition disappeared, while adjustment for PE 18:0/22:6 levels did not change the association of PE 18:0/22:6 with cognition. These findings suggest that PL 18:0/22:6 is an independent predictor of cognition and the association of PE 18:0/22:6 with cognition is spurious, and probably reflects the homeostatic adjustment of PE levels due to PL deficiency (Dorninger et al., 2015). Association of higher PL 18:0/22:6 levels (>mean+1SD) with normal cognition and the association of lower levels (<mean-1SD) with dementia is suggestive of protective effects at higher levels and deleterious effects at lower brain levels.

Flotillin is a marker of lipid rafts in the brain (Dermine et al., 2001). Lipid rafts are cholesterol and sphingolipid-enriched areas in the membrane that help sequester certain proteins. Lipid rafts are known to be associated with gamma-secretase that generate amyloid β-protein (Aβ) and thought to promote the interaction of the amyloid precursor protein (APP) with gamma-secretase (Matsumura et al., 2014). The apparent enhancement of the negative association of flotillin with cognition by PL 18:0/22:6 probably indicate modification of membrane structure by PL 18:0/22:6. In fact, it has been shown that increasing membrane DHA-PL levels dose dependently increased soluble APPα and decreased gamma-secretase expression (Wood et al., 2011a).

Recent research findings suggest that the onset of AD neuropathological changes occur years prior to the appearance of clinical symptoms (Sperling et al., 2014). Exploring biochemical changes associated with early pathophysiological events is crucial to finding modifiable risk factors that can be used for primary and secondary prevention (Sperling et al., 2011). PL deficiency in the brain is one such biochemical change reported to be associated with brain pathology and cognition (Ginsberg et al., 1995; Han et al., 2001; Goodenowe et al., 2007; Wood et al., 2010; Goodenowe and Senanayake, 2019). We recently reported that higher levels of serum plasmalogens weaken or nullify the associations between age and APOE e4 allele status and AD and...
cognition (Goodenowe and Senanayake, 2019) and that increasing circulating DHA plasmalogens levels using a plasmalogen precursor had positive effects on cognition and mobility (Goodenowe et al., 2022).

Glycerophospholipids containing a vinyl ether bond at sn-1 are called plasmalogens. They are synthesized via a single non-redundant biochemical pathway in intracellular organelles called peroxisomes (Brites et al., 2004). A decline in peroxisomal function due to aging leads to low PL levels in the membranes and lipoproteins in the brain causing defective membrane function (Farooqui et al., 1997) and aberrations in brain cholesterol metabolism (Goodenowe and Senanayake, 2019). These two factors lead to suboptimal cholinergic neuron function (Blusztajn and Wurtman, 1983) and atrophy and defects in amyloid clearance respectively (Sun et al., 2015), presumably leading to brain pathology characteristic of AD. PL predominates in the body over choline plasmalogens (Farooqui and Horrocks, 2001) and they play a significant role in maintaining optimal brain function (Rouser and Yamamoto, 1968; Farooqui et al., 2008). These phospholipids are associated with cellular membranes in the brain and are involved in multiple brain functions including cholesterol metabolism, synaptic function, and APP processing (Farooqui and Horrocks, 2001; Brites et al., 2004; Rothhaar et al., 2012). Alteration of membrane function is hypothesized to be mechanistically linked to the pathology and clinical symptoms observed in AD (Glaser and Gross, 1995; Askarova et al., 2011).

The study has several limitations. First it was designed to focus on a single class of lipids in a single brain region to investigate specific membrane structural changes with pathology and cognition. Extrapolation of the results to other lipid classes or brain regions or the contributions of other brain regions or other pathologies or other phospholipids to cognition was not investigated. Upstream (impaired peroxisomal function) or downstream (high levels of inflammation/oxidative stress) causal factors that may simultaneously influence PL levels and cognition was not investigated. Future studies are needed to further explore and define the roles of additional contributing factors such as these in the outcomes observed and reported in this study.

This is the first reported evidence of a potential modifiable risk factor that can modulate the effects of brain pathology on cognition possibly through membrane alterations. This report also demonstrates the spurious association of DHA-phosphatide with cognition and unequivocally demonstrates the significance of DHA-plasmalogens on cognition. Increasing DHA-plasmalogen levels in the brain might have the potential to modify the neurodegenerative pathways responsible for cognitive deficits.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Rush University. The patients/participants provided their written informed consent to participate in this study.

Author contributions

DG and VS equally contributed to the data analysis and preparation of the initial draft manuscript. DG was responsible for the design of the study, final interpretation of the results and final manuscript revisions.

Acknowledgments

We wish to thank David A. Bennett and Sue E. Leurgans for critical discussions and review of the statistical results their valuable suggestions. We acknowledge and thank Rush University Alzheimer’s Disease Center for providing the brain samples.

Conflict of interest

The corresponding author is the CEO and President of Prodrome Sciences USA LLC. Second author was an employee of Prodrome Sciences USA LLC.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Goodenowe and Senanayake (2018). Alzheimer’s Disease Facts and Figures. *Alzheimers Dement.* 14 (3), 367–429.

Asarova, S., Yang, X., and Lee, J. C. (2011). Impacts of membrane biophysics in Alzheimer’s disease: From amyloid precursor protein processing to αβ peptide-induced membrane changes. *Int. J. Alzheimers Dis.* 2011, 134971. doi:10.4061/2011/134971

Asturita, G., Jung, K. M., Berchtold, N. C., Nguyen, V. Q., Gillen, D. L., Head, E., et al. (2010). Deficient liver biosynthesis of diocosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. *PLoS ONE* 5, 0012338. doi:10.1371/journal.pone.0012338

Bancher, C., Braak, H., Fischer, P., and Jellinger, K. (1993). Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer’s and Parkinson’s disease patients. *Neurosci. Lett.* 162, 179–182. doi:10.1016/0304-3940(93)90590-h

Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., et al. (2006). Neuropathology of older persons without cognitive impairment from two community-based studies. *Neurology* 66, 1837–1844. doi:10.1212/01.wnl.0000203870.05648.ce

Bennett, D. A., Schneider, J. A., Buchman, A. S., Barnes, L. L., Boyle, P. A., Wilson, R. S., et al. (2012). Overview and findings from the rush memory and aging Project. *Curr. Alzheimers Res.* 9, 646–663. doi:10.2174/156725212801322663

Blustajn, J. K., and Wurtman, R. J. (1983). Choline and cholinergic neurons. *Science* 221, 614–620. doi:10.1126/science.667732

Braak, H., and Braak, E. (1997). Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol. Aging* 18, 351–357. doi:10.1016/0197-4580(97)00056-0

Braak, H., and Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 82, 239–259. doi:10.1007/BF00308909

Braak, H., Braak, E., Yilmazer, D., de Vos, R. A., Jansen, E. N., Bohl, J., et al. (1996). Pattern of brain destruction in Parkinson’s and Alzheimer’s disease. *J. Neural Transm.* 103, 455–490. doi:10.1007/s004290050174

Brites, P., Waterham, H. R., and Wanders, R. J. (2004). Functions and biosynthesis of plasmalogens in health and disease. *Biochim. Biophys. Acta* 1636, 219–231. doi:10.1016/j.bbadis.2003.12.010

Cordy, J. M., Hussain, I., Dingwall, C., Hooper, N. M., and Turner, A. J. (2003). Exclusively targeting beta-secretase to lipid rafts by GPCR-anchor addition up-regulates beta-site processing of the amyloid precursor protein. *Proc. Natl. Acad. Sci. U. S. A.* 100, 11735–11740. doi:10.1073/pnas.1635131100

Dermine, J. F., Duclos, S., Garim, J. St-Louis, F., Rea, S., Parton, R. G., et al. (2001). Flotillin-1 enriched lipid raft domains accumulate on maturing phagosomes. *J. Biol. Chem.* 276, 18507–18512. doi:10.1074/jbc.M10113200

Dorninger, F., Brodde, A., Braverman, N. E., Moser, A. B., Just, W. W., Forss-Fatouros, I., Glaser, P. E., and Gross, R. W. (1995). Rapid plasmenylethanolamine-selective phosphorylation in normal and injured neurons and glia. *Brain Sci.* 5, 646–663. doi:10.2174/156725212801322663

Ferguson, S. M., Savchenko, V., Apparsundaram, S., Zwick, M., Wright, J., Mochizuki, A., et al. (2016). Plasmalogen augmentation reverses striatal levodopa-induced dyskinesias in parkinsonian monkeys. *Behav. Brain Res.* 286, 328–337. doi:10.1016/j.bbr.2015.07.012

Han, X., Holteman, D. M., and McKee, D. W., Jr. (2001). Plasmanolgen deficiency in early Alzheimer’s disease subjects and in animal models. Molecular characterization using electrospray ionization mass spectrometry. *J. Neurochem.* 77, 1168–1180. doi:10.1046/j.1471-4159.2001.00332.x

Han, X. (2005). Lipid alterations in the earliest clinically recognizable stage of Alzheimer’s disease: Implication of the role of lipids in the pathogenesis of Alzheimer’s disease. *Curr. Alzheimers Res.* 2, 65–77. doi:10.2174/156725205527272876

Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. *Science* 297, 353–356. doi:10.1126/science.1072994

Igarashi, M., Ma, K., Gao, F., Kim, H. W., Rapoport, S. I., Rao, J. S., et al. (2011). Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer’s disease prefrontal cortex. *J. Alzheimers Dis.* 24, 507–517. doi:10.3233/JAD-2011-101608

Kejro, E., Gimpl, G., Lammich, S., Marz, W., and Fahrenholz, F. (2001). Low cholesterolem stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. *Proc. Natl. Acad. Sci. U. S. A.* 98, 5815–5820. doi:10.1073/pnas.081612998

Kozin, S. A., Rarykin, E. P., Mitkevich, V. A., and Makarov, A. A. (2018). Anti-amyloid therapy of Alzheimer’s disease: Current state and prospects. *Biochemistry* 83, 1057–1067. doi:10.1002/1530-6989.201809079

Lobner, K. (1996). Is the high propensivity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembrane? *Chem. Phys. Lipids* 81, 167–184. doi:10.1016/0009-9133(96)00258-7

Maire, J. C., and Wurtman, R. J. (1985). Effects of electrical stimulation and choline availability on the release and contents of acetylcholine and choline in superfused slices from rat striatum. *J. Pharmacol. Exp. Ther.* 80, 189–195.

Mankidy, R., Ahiahonu, P. W., Ma, H., Jayasinghe, D., Ritchie, A. S., Khanna, M. A., et al. (2010). Membrane plasmalogen composition and cellular cholesterol regulation: A structure activity study. *Lipids Health Dis.* 9, 62. doi:10.1186/1476-511X-9-42

Matsunuma, N., Takami, M., Okochi, M., Wada-Kakuda, S., Fujisawa, H., Tagami, S., et al. (2014). γ-secretase associated with lipid rafts: Multiple interactive pathways in the stepwise processing of β-carboxyl-terminal fragment. *J. Biol. Chem.* 289, 5109–5121. doi:10.1074/jbc.M113.151011

Miville-Godbout, E., Bourque, M., Morissette, M., Al-Sweidi, S., Smith, T., Mochizuki, A., et al. (2016). Plasmalogen augmentation reverses striatal dopamine loss in MPTP mice. *PLoS One* 11, e0151020. doi:10.1371/journal.pone.0151020

Negash, S., Bennett, D. A., Wilson, R. S., Schneider, J. A., and Arnold, S. E. (2011). Cognition and neuropathology in aging: Multidimensional perspectives from the rush religious orders study and rush memory and aging Project. *Curr. Alzheimers Res.* 8, 336–340. doi:10.2174/156725011795745302
Nitsch, R. M., Blusztajn, J. K., Pittas, A. G., Slack, B. E., Growdon, J. H., Wurtman, R. J., et al. (1992). Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. U. S. A. 89, 1673–1675. doi:10.1073/pnas.89.5.1671

Otohi, Y., Kato, S., Nakagawa, K., Harvey, D. J., Jin, L. W., Dugger, B. N., et al. (2021). Lipidomic analysis of postmortem prefrontal cortex phospholipids reveals changes in choline plasmalogens containing docosahexaenoic acid and stearic acid between cases with and without Alzheimer’s disease. Neuropeptide Med. 23, 161–175. doi:10.1007/s12017-020-08636-w

Ritchie, S. A., Jayasinge, D., Wang, L., and Goodenowe, D. B. (2016). Improved specificity of serum phosphatidylcholine detection based on side-chain losses during negative electrospray ionization tandem mass spectrometry. Anal. Bioanal. Chem. 408, 7811–7823. doi:10.1007/s00216-016-9884-2

Rothhaar, T. L., Grosgen, S., Haupenthal, V. J., Burg, V. K., Hundsdorfer, B., Mett, J., et al. (2012). Plasmalogens inhibit APP processing by directly affecting gamma-secretase activity in Alzheimer’s disease. ScientificWorldJournal. 2012, 141240. doi:10.1100/2012/141240

Rouser, G., and Yamamoto, A. (1968). Curvilinear regression course of human brain lipid composition changes with age. Lipids 3, 284–287. doi:10.1007/ BF02531202

Scheff, S. W., Price, D. A., Schmitt, F. A., Scheff, M. A., and Mufson, E. J. (2011). Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer’s disease. J. Alzheimers Dis. 24, 547–557. doi:10.3233/JAD-2011-101782

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the national institute on aging-alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 280–292. doi:10.1016/j.dadm.2011.03.003

Sperling, R., Mormino, E., and Johnson, K. (2014). The evolution of preclinical alzheimer’s disease: Implications for prevention trials. Neuron 84, 608–622. doi:10.1016/j.neuron.2014.10.038

Sun, J. H., Yu, J. T., and Tan, L. (2015). The role of cholesterol metabolism in Alzheimer’s disease. Mol. Neurobiol. 51, 947–965. doi:10.1007/s12035-014-8749-y

Ulus, I. H., Wurtman, R. J., Mauron, C., and Blusztajn, J. K. (1989). Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum. Brain Res. 484, 217–227. doi:10.1016/0006-8993(89)90364-8

Wood, P. L., Khan, A. M., Mankidy, R., Smith, T., and Goodenowe, D. (2011). “Plasmalogens deficit: A new and testable hypothesis for the etiology of Alzheimer’s disease,” in Alzheimer’s disease pathogenesis-core concepts, shifting paradigms and therapeutic targets. Editor S. De la Monte (India: InTech).

Wood, P. L., Mankidy, R., Ritchie, S., Heath, D., Wood, J. A., Flax, J., et al. (2010). Circulating plasmalogen levels and alzheimer disease assessment scale-cognitive scores in alzheimer patients. J. Psychiatry Neurosci. 35, 59–62. doi:10.1503/jpn.090059

Wood, P. L., Smith, T., Lane, N., Khan, M. A., Ehmantraut, G., Goodenowe, D. B., et al. (2011). Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: A new therapeutic strategy for alzheimer’s disease. Lipids Health Dis. 10, 227. doi:10.1186/1476-511X-10-227

Wurtman, R. J., Blusztajn, J. K., and Maure, J.-C. (1985). “Autocannibalism” of choline-containing membrane phospholipids in the pathogenesis of Alzheimer’s disease-A hypothesis. Neurochem. Int. 7, 369–372. doi:10.1016/0197-0186(85)90127-5

Wurtman, R. J. (1992). Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci. 15, 117–122. doi:10.1016/ 0166-2236(92)90351-8

Xie, J., Brayne, C., Matthews, F. E., and Medical Research Council Cognitive, F. (2008). Survival times in people with dementia: Analysis from population based cohort study with 14 year follow-up. BMJ 336, 258–262. doi:10.1136/bmj.39433. 616678.25

Yang, Z., Gou, L., Chen, S., Li, N., Zhang, S., Zhang, L., et al. (2017). Membrane fusion involved in neurotransmission: Glimpse from electron microscope and molecular simulation. Front. Mol. Neurosci. 10, 168. doi:10.3389/fnmol.2017.00168

Yu, L., Boyle, P., Schneider, J. A., Segawa, E., Wilson, R. S., Leurgans, S., et al. (2013). APOE ε4, Alzheimer’s disease pathology, cerebrovascular disease, and cognitive change over the years prior to death. Psychol. Aging 28, 1015–1023. doi:10.1037/a0031642

Yu, L., Dawe, R. J., Boyle, P. A., Gaiteri, C., Yang, J., Buchman, A. S., et al. (2017). Association between brain gene expression, DNA methylation, and alteration of ex vivo magnetic resonance imaging transverse relaxation in late-life cognitive decline. JAMA Neuro. 74, 1473–1480. doi:10.1001/jamaneurol.2017.2807